Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated (NYSE: DGX) files reports with the U.S. Securities and Exchange Commission that provide formal insight into its operations as a medical laboratories company focused on diagnostic testing and diagnostic information services. On this page, investors can review Quest Diagnostics’ SEC filings alongside AI-powered tools that help explain the content and context of these documents.
Quest Diagnostics uses current reports on Form 8-K to disclose material events such as quarterly financial results and investor presentations. For example, the company has filed 8-Ks to announce results for specific quarters and to furnish presentation materials used at the J.P. Morgan Healthcare Conference, covering topics such as strategy, performance and market developments. These filings give investors structured access to information that the company shares with the market.
In addition to 8-Ks, users can expect to find Quest Diagnostics’ periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain detailed discussions of business segments, risk factors and financial condition. While these specific forms are not reproduced in the provided data, they are standard components of a public company’s SEC reporting and are accessible through this filings page.
The platform enhances these documents with AI-generated summaries that highlight key points, helping users navigate complex language and lengthy sections. For instance, AI tools can surface main themes from a 10-K, summarize quarterly performance from a 10-Q or clarify the significance of information furnished in an 8-K. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly.
Investors interested in governance, capital allocation and executive communications can use this page to monitor Quest Diagnostics’ regulatory disclosures, while AI assistance streamlines the process of reviewing and interpreting the company’s filings.
Quest Diagnostics senior vice president and chief commercial officer Mark E. Delaney reported multiple equity-related transactions. On February 18, 2026, he was granted a non-qualified stock option for 7,332 shares, which vests in three equal annual installments beginning on the first anniversary of the grant date. He also received 1,586 shares of common stock, which the footnotes describe as an award of restricted stock units. On the same date, 205 shares at $210.01 and 230 shares at $206.99 of common stock were disposed of back to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Separately, on January 28, 2026, he acquired 15 shares of common stock through a dividend reinvestment plan, which the rules allow to be reported later on Form 5 but he chose to report on this Form 4.
Quest Diagnostics SVP and Chief Accounting Officer Michael J. Deppe reported a mix of equity grants and related tax share withholdings. On February 18, 2026, he was granted a non‑qualified stock option covering 1,688 shares, which vests in three equal annual installments beginning on the first anniversary of the grant date.
He also received an award of 366 restricted stock units. To cover tax withholding from vesting RSUs, 83 shares of common stock at
Quest Diagnostics director Wright Lassiter III reported acquiring 7 shares of common stock on January 28, 2026 at $183.51 per share. The filing states these shares were obtained through a broker-administered dividend reinvestment plan and are eligible for deferred reporting under Rule 16a-6, but were reported early on Form 4. Following this small acquisition, his directly held position increased to 9,057 shares, a figure that includes shares previously acquired via dividend reinvestment since his last Form 4 filing.
Quest Diagnostics director Robert B. Carter reported a small acquisition of company stock through a dividend reinvestment plan. On January 28, 2026, he acquired 6 shares of common stock at $183.51 per share. Following this routine reinvestment, he directly owns 2,704 shares of Quest Diagnostics common stock. The transaction was eligible for later reporting on Form 5, but he chose to report it early on this Form 4.
Quest Diagnostics director Vicky B. Gregg reported a small automatic share acquisition. On January 28, 2026, she acquired 67 shares of common stock at $183.513 per share through a broker-administered dividend reinvestment plan, bringing her direct holdings to 17,104 shares. The transaction was voluntarily reported early on Form 4, even though it was eligible for deferred reporting on Form 5 under Rule 16a-6.
DGX reported a Form 144 notice relating to proposed or completed sales of common stock by an insider. The filing shows a reported sale of 5,662 shares on
Quest Diagnostics reported an insider sale and recent restricted stock vesting. Catherine T. Doherty sold 26,165 Common shares on 02/13/2026 for $5,393,815.32. The filing also lists restricted stock vesting of 726 shares on 02/12/2026 and 707 shares on 02/14/2026, each labeled as Issuer compensation.
DGX filed a Form 144 indicating planned sales of common stock following restricted stock vesting. The notice lists 480 shares with a 02/12/2026 date and 631 shares with a 02/14/2026 date, with transactions routed through Fidelity Brokerage Services LLC.
Quest Diagnostics EVP Catherine T. Doherty reported an option exercise and related share sales. On 02/13/2026 she exercised 26,165 non-qualified stock options at
That day she sold 26,165 common shares in several open-market transactions at weighted average prices between
A shareholder of DGX has filed a notice under Rule 144 to sell 26,165 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 02/13/2026. The filing lists an aggregate market value of these shares of